What You Should Know: – DarioHealth Corp., a provider of global digital therapeutics (DTx), announced it has entered into a $30M multi-year, strategic agreement with Sanofi U.S., an innovative global healthcare company. The multi-year, $30 million-dollar agreement will help accelerate commercial adoption of Dario’s full suite of digital therapeutics and drive the expansion of digital health […]

Later this year, Fulcrum Therapeutics will launch a Phase III study of losmapimod in people with facioscapulohumeral muscular dystrophy (FSHD), hoping to become the company to produce the first approved drug aimed at one of the most common forms of the disease. Fulcrum’s Phase III REACH trial of losmapimod in this indication, builds on the Phase IIb ReDUX4 study […]

DarioHealth has beefed up its sales and marketing channels as well as its range of digital health products thanks to a $30 million strategic alliance with drugmaker Sanofi. Under the terms of the five-year deal, Sanofi digital health apps will be integrated into Dario’s platform and Sanofi’s sales muscle will be deployed to market the […]